FCH
VKTX icon

Freestone Capital Holdings’s Viking Therapeutics VKTX Stock Holding History

Freestone Capital Holdings’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-66,417
Closed -$1.75M – 603
2025
Q3 		$1.75M Buy
+66,417
New +$1.98M 0.05% 194

Other funds holding VKTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Freestone Capital Holdings's VKTX Position: Q4 2025 in Review

Freestone Capital Holdings sold out of Viking Therapeutics (VKTX) in Q4 2025, closing a stake of 66,417 shares — an estimated $1.75M sold.

Freestone Capital Holdings first reported a position in VKTX in Q3 2025 and held it in 1 quarter. The position peaked at $1.75M in Q3 2025. 427 funds tracked by Wall St. Rank hold VKTX as of Q4 2025.

  • Freestone Capital Holdings reported no remaining Viking Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Freestone Capital Holdings sold 66,417 Viking Therapeutics shares in Q4 2025, an estimated $1.75M.
  • Freestone Capital Holdings first reported a position in Viking Therapeutics in Q3 2025 and held it in 1 quarter.
  • Freestone Capital Holdings's Viking Therapeutics position peaked at $1.75M in Q3 2025.
  • 427 funds tracked by Wall St. Rank held Viking Therapeutics as of Q4 2025.

Based on Freestone Capital Holdings's 13F filing for Q4 2025, filed 23 Jan 2026.